Exhibit 99.1
 |
Sanuwave announces Q1 2023 financial results
SANUWAVE Health, Inc.
EDEN PRAIRIE, MN, May 12, 2023
SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced 1st quarter 2023 results.
For the three-months ended March 31, 2023:
| • |
Revenues increased 18% to $3.8 million for Q1 2023 versus $3.2 million for the same period last year. This growth falls within the guidance range of 14-20%, provided on the prior conference call.
|
| • |
UltraMist® systems sold increased 12% to 28 for Q1 2023, versus 25 systems for the same period last year.
|
| • |
UltraMist® applicator cases sold increased 18% to 3,641, versus 3,093 applicator cases for the same period last year.
|
| • |
Gross margin as a percentage of revenue decreased for the three months ended March 31, 2023, to 67% from 72% for the same period last year.
|
| • |
Operating loss totaled $2.0 million for the three months ended March 31, 2023, which was flat compared to the same period last year.
|
| • |
We anticipate second quarter revenue growth to fall within a range of 15-25%.
|
Mr. Kevin Richardson, CEO, stated, “We are very pleased with the strong interest we observed from customers at the three conferences we attended. The Third Annual
Leaders in Wound Healing Conference in New Orleans, the Symposium on Advanced Wood Care Spring (SAWC Spring) in National Harbor, MD, and EWMA 2023 Symposium in Milan, Italy.
These conferences were an ideal platform for us to showcase our innovative non-invasive, regenerative medicine solutions for the treatment of chronic wounds.
SANUWAVE Health is committed to advancing the field of regenerative medicine and improving patient care. The company's groundbreaking technology has been shown to
accelerate the healing of chronic wounds, leading to improved patient outcomes and reduced healthcare costs."
Subsequent to the end of the quarter, the company raised an additional approximately $1.2 million in order to maximize flexibility around sales hiring and inventory
build. Terms were consistent with the previous financing. This cash is not reflected in the Q1 statements.
Guidance
The Company has continued to have constrained inventory supply during Q1 2023. Despite this, we anticipate revenue growth of approximately 15% to 25% during Q2 2023,
compared to Q2 2022. The company believes that supply is further improving and that we will observe continued increase in revenue growth in Q2 2023.
As previously announced a business update will occur via conference call on May 12, 2022. Materials for the conference call at 9:00 a.m. EST are included on the company
website, www.sanuwave.com/investors.
Telephone access is available by dialing the following numbers:
Conference ID: 13738852
Toll-Free: 1-877-407-0784
Toll/International: 1-201-689-8560
A replay will be available through May 26, shortly after conclusion of the event.
About SANUWAVE
SANUWAVE Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the
repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
SANUWAVE’s end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. SANUWAVE applies and
researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as
statements relating to financial results and plans for future business development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current
expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s
ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks
associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues,
competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
CONTACT:
Kevin Richardson, II
Chief Executive Officer
Investors@Sanuwave.com
PART I -- FINANCIAL INFORMATION
|
ITEM 1.
|
FINANCIAL STATEMENTS
|
SANUWAVE HEALTH, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(In thousands, except share data)
|
March 31, 2023
|
December 31, 2022
|
|||||||
|
ASSETS
|
||||||||
|
Current Assets:
|
||||||||
|
Cash
|
$
|
106
|
$
|
1,153
|
||||
|
Accounts receivable, net of allowance of $1.2 and $1.0 million, respectively
|
2,969
|
4,029
|
||||||
|
Inventory
|
1,071
|
868
|
||||||
|
Prepaid expenses and other current assets
|
371
|
570
|
||||||
|
Total Current Assets
|
4,517
|
6,620
|
||||||
|
Property, Equipment and Other, net
|
758
|
856
|
||||||
|
Intangible Assets, net
|
4,962
|
5,137
|
||||||
|
Goodwill
|
7,260
|
7,260
|
||||||
|
Total Non-current Assets
|
12,980
|
13,253
|
||||||
|
Total Assets
|
$
|
17,497
|
$
|
19,873
|
||||
|
LIABILITIES
|
||||||||
|
Current Liabilities:
|
||||||||
|
Senior secured debt, in default
|
$
|
14,996
|
$
|
14,416
|
||||
|
Convertible promissory notes payable
|
16,953
|
16,713
|
||||||
|
Convertible promissory notes payable, related parties
|
7,614
|
7,409
|
||||||
|
Accounts payable
|
5,264
|
4,400
|
||||||
|
Accrued expenses
|
8,550
|
8,512
|
||||||
|
Due under factoring ageement
|
1,631
|
2,130
|
||||||
|
Warrant liability
|
9,264
|
1,416
|
||||||
|
Accrued interest
|
4,981
|
4,052
|
||||||
|
Accrued interest, related parties
|
1,081
|
788
|
||||||
|
Current portion of contract liabilities
|
62
|
60
|
||||||
|
Other
|
255
|
291
|
||||||
|
Total Current Liabilities
|
70,651
|
60,187
|
||||||
|
Non-current Liabilities
|
||||||||
|
Lease liabilities
|
384
|
438
|
||||||
|
Contract liabilities
|
225
|
230
|
||||||
|
Deferred tax liability
|
28
|
28
|
||||||
|
Total Non-currrent Liabilities
|
637
|
696
|
||||||
|
Total Liabilities
|
$
|
71,288
|
$
|
60,883
|
||||
|
Commitments and Contingencies (Footnote 11)
|
||||||||
|
STOCKHOLDERS' DEFICIT
|
||||||||
|
Preferred Stock, par value $0.001, 5,000,000 shares authorized;
|
||||||||
|
6,175 shares Series A, 293 shares Series B, 90 shares Series C and 8 shares Series D
no shares issued and outstanding at March 31, 2023 and December 31, 2022
|
$
|
-
|
$
|
-
|
||||
|
Common Stock, par value $0.001, 2,500,000,000 shares authorized; 555,637,651 and 548,737,651
issued and outstanding at March 31, 2023 December 31, 2022, respectively
|
556
|
549
|
||||||
|
Additional Paid-in Capital
|
153,046
|
152,750
|
||||||
|
Accumulated Deficit
|
(207,322
|
)
|
(194,242
|
)
|
||||
|
Accumulated Other Comprehensive Loss
|
(71
|
)
|
(67
|
)
|
||||
|
Total Stockholders' Deficit
|
(53,791
|
)
|
(41,010
|
)
|
||||
|
Total Liabilities and Stockholders' Deficit
|
$
|
17,497
|
$
|
19,873
|
||||
The accompanying notes to condensed consolidated financial statement are an integral part of these financial statements.
SANUWAVE HEALTH, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(UNAUDITED)
(In thousands, except share data)
|
Three Months Ended March 31,
|
||||||||
|
2023
|
2022
|
|||||||
|
Revenue
|
$
|
3,775
|
$
|
3,195
|
||||
|
Cost of Revenues
|
1,262
|
889
|
||||||
|
Gross Margin
|
2,513
|
2,306
|
||||||
|
Operating Expenses:
|
||||||||
|
General and administrative
|
2,759
|
2,205
|
||||||
|
Selling and marketing
|
1,412
|
1,715
|
||||||
|
Research and development
|
131
|
166
|
||||||
|
Depreciation and amortization
|
189
|
176
|
||||||
|
Total Operating Expenses
|
4,491
|
4,262
|
||||||
|
Operating Loss
|
(1,978
|
)
|
(1,956
|
)
|
||||
|
Other Income (Expense):
|
||||||||
|
Interest expense
|
(3,512
|
)
|
(3,136
|
)
|
||||
|
Interest expense, related party
|
(766
|
)
|
(56
|
)
|
||||
|
Change in fair value of derivative liabilities
|
(6,797
|
)
|
3,482
|
|||||
|
Loss on issuance of debt
|
-
|
(3,434
|
)
|
|||||
|
Other expense
|
(27
|
)
|
-
|
|||||
|
Gain / (loss) on foreign currency exchange
|
-
|
(1
|
)
|
|||||
|
Total Other Expense
|
(11,102
|
)
|
(3,145
|
)
|
||||
|
Net Loss before Income Taxes
|
(13,080
|
)
|
(5,101
|
)
|
||||
|
Provision for Income Taxes
|
-
|
-
|
||||||
|
Net Loss
|
(13,080
|
)
|
(5,101
|
)
|
||||
|
Other Comprehensive Loss
|
||||||||
|
Foreign currency translation adjustments
|
(4
|
)
|
-
|
|||||
|
Total Comprehensive Loss
|
$
|
(13,084
|
)
|
$
|
(5,101
|
)
|
||
|
Loss per Share:
|
||||||||
|
Basic and Diluted
|
$
|
(0.02
|
)
|
$
|
(0.01
|
)
|
||
|
Weighted average shares outstanding, basic and diluted
|
575,028,811
|
525,414,534
|
||||||
The accompanying notes to condensed consolidated financial statements are an integral part of these financial statements.
SANUWAVE HEALTH, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT
(UNAUDITED)
(In thousands, except share data)
|
Three Months Ended March 31, 2023
|
||||||||||||||||||||||||||||||||
|
Preferred Stock
|
Common Stock
|
|||||||||||||||||||||||||||||||
|
Number of
Shares |
Number of
Shares |
Additional Paid-
|
Accumulated
|
Accumulated
Other |
||||||||||||||||||||||||||||
|
Outstanding
|
Par Value
|
Outstanding
|
Par Value
|
in Capital
|
Deficit
|
Loss
|
Total
|
|||||||||||||||||||||||||
|
Balances as of December 31, 2022
|
-
|
$
|
-
|
548,737,651
|
$
|
549
|
$
|
152,750
|
$
|
(194,242
|
)
|
$
|
(67
|
)
|
$
|
(41,010
|
)
|
|||||||||||||||
|
Shares issued for services
|
-
|
-
|
6,900,000
|
7
|
296
|
-
|
303
|
|||||||||||||||||||||||||
|
Net loss
|
-
|
-
|
-
|
-
|
-
|
(13,080
|
)
|
-
|
(13,080
|
)
|
||||||||||||||||||||||
|
Foreign currency translation adjustment
|
-
|
-
|
-
|
-
|
-
|
-
|
(4
|
)
|
(4
|
)
|
||||||||||||||||||||||
|
Balances as of March 31, 2023
|
-
|
$
|
-
|
555,637,651
|
$
|
556
|
$
|
153,046
|
$
|
(207,322
|
)
|
$
|
(71
|
)
|
$
|
(53,791
|
)
|
|||||||||||||||
|
Three Months Ended March 31, 2022
|
||||||||||||||||||||||||||||||||
|
Preferred Stock
|
Common Stock
|
|||||||||||||||||||||||||||||||
|
Number of
Shares |
Number of
Shares |
Additional Paid-
|
Accumulated
|
Accumulated
Other |
||||||||||||||||||||||||||||
|
Outstanding
|
Par Value
|
Outstanding
|
Par Value
|
in Capital
|
Deficit
|
Loss
|
Total
|
|||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||
|
Balances as of December 31, 2021
|
-
|
$
|
-
|
481,619,621
|
$
|
482
|
$
|
144,582
|
$
|
(183,949
|
)
|
$
|
(73
|
)
|
$
|
(38,958
|
)
|
|||||||||||||||
|
Cashless warrant exercise
|
-
|
-
|
14,000,000
|
14
|
2,152
|
-
|
-
|
2,166
|
||||||||||||||||||||||||
|
Warrant exercise
|
-
|
-
|
909,091
|
1
|
99
|
-
|
-
|
100
|
||||||||||||||||||||||||
|
Shares issued in conjunction with Note Payable
|
-
|
-
|
20,666,993
|
20
|
3,700
|
-
|
-
|
3,720
|
||||||||||||||||||||||||
|
Net loss
|
-
|
-
|
-
|
-
|
-
|
(5,101
|
)
|
-
|
(5,101
|
)
|
||||||||||||||||||||||
|
Foreign currency translation adjustment
|
-
|
-
|
-
|
-
|
-
|
-
|
6
|
6
|
||||||||||||||||||||||||
|
Balances as of March 31, 2022
|
-
|
$
|
-
|
517,195,705
|
$
|
517
|
$
|
150,533
|
$
|
(189,050
|
)
|
$
|
(67
|
)
|
$
|
(38,067
|
)
|
|||||||||||||||
The accompanying notes to condensed consolidated financial statements are an integral part of these financial statements.
SANUWAVE HEALTH, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(In thousands)
|
Three Months Ended March 31,
|
||||||||
|
2023
|
2022
|
|||||||
|
Cash Flows - Operating Acivities:
|
||||||||
|
Net loss
|
$
|
(13,080
|
)
|
$
|
(5,101
|
)
|
||
|
Adjustments to reconcile net loss to net cash used by operating activities
|
||||||||
|
Depreciation and Amortization
|
259
|
191
|
||||||
|
Bad debt expense
|
156
|
-
|
||||||
|
Change in fair value of derivative liabilities
|
6,797
|
(3,482
|
)
|
|||||
|
Loss on issuance of debt
|
-
|
3,434
|
||||||
|
Amortization of debt issuance costs and original issue discount
|
1,931
|
889
|
||||||
|
Accrued interest
|
1,365
|
667
|
||||||
|
Changes in operating assets and liabilities
|
||||||||
|
Accounts receivable - trade
|
906
|
804
|
||||||
|
Inventory
|
(203
|
)
|
39
|
|||||
|
Prepaid expenses and other assets
|
195
|
4
|
||||||
|
Accounts payable
|
864
|
(866
|
)
|
|||||
|
Accrued expenses
|
450
|
444
|
||||||
|
Contract liabilties
|
(11
|
)
|
(155
|
)
|
||||
|
Net Cash Used in Operating Activities
|
(371
|
)
|
(3,132
|
)
|
||||
|
Cash Flows - Investing Activities
|
||||||||
|
Proceeds from sale of property and equipment
|
-
|
360
|
||||||
|
Purchase of property and equipment
|
(18
|
)
|
-
|
|||||
|
Net Cash Flows Provided by (Used in) Investing Activities
|
(18
|
)
|
360
|
|||||
|
Cash Flows - Financing Activities
|
||||||||
|
Proceeds from senior promissory notes
|
-
|
2,940
|
||||||
|
Payments to factoring agent, net
|
(610
|
)
|
(505
|
)
|
||||
|
Proceeds from warrant exercises
|
-
|
100
|
||||||
|
Payments of principal on finance leases
|
(44
|
)
|
(65
|
)
|
||||
|
Net Cash Flows Provided by Financing Activities
|
(654
|
)
|
2,470
|
|||||
|
Effect of Exchange Rates on Cash
|
(4
|
)
|
(4
|
)
|
||||
|
Net Change in Cash During Period
|
(1,047
|
)
|
(306
|
)
|
||||
|
Cash at Beginning of Period
|
1,153
|
619
|
||||||
|
Cash at End of Period
|
$
|
106
|
$
|
313
|
||||
|
Supplemental Information:
|
||||||||
|
Cash paid for interest
|
$
|
908
|
$
|
574
|
||||
|
Non-cash Investing and Financing Activities:
|
||||||||
|
Reclassification of warrant liability due to cashless warrant exercise
|
$
|
-
|
$
|
2,167
|
||||
|
Warrants issued in conjunction with senior secured promissory note payable
|
-
|
2,654
|
||||||
|
Common shares issued in conjunction with senior secured promissory note payable
|
-
|
3,720
|
||||||
|
Common shares issued for advisory shares
|
302
|
-
|
||||||
The accompanying notes to condensed consolidated financial statements are an integral part of these financial statements.